|
Eine Ebene nach oben |
Gruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 3
Zeitschriftenartikel
Friedl, Thomas W. P.; Fehm, Tanja; Mueller, Volkmar; Lichtenegger, Werner; Blohmer, Jens; Lorenz, Ralf; Forstbauer, Helmut; Fink, Visnja; Bekes, Inga; Huober, Jens; Jueckstock, Julia; Schneeweiss, Andreas; Tesch, Hans; Mahner, Sven; Brucker, Sara Y.; Heinrich, Georg; Haeberle, Lothar; Fasching, Peter A.; Beckmann, Matthias W.; Coleman, Robert E.; Janni, Wolfgang und Rack, Brigitte
(2021):
Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment A Phase 3 Randomized Clinical Trial.
In: Jama Oncology, Bd. 7, Nr. 8: S. 1149-1157
Yardley, Denise A.; Brufsky, Adam; Coleman, Robert E.; Conte, Pierfranco F.; Cortes, Javier; Glück, Stefan; Nabholtz, Jean-Mark A.; O'Shaughnessy, Joyce; Beck, Robert M.; Ko, Amy; Renschler, Markus F.; Barton, Debora und Harbeck, Nadia
(2016):
Erratum to: Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial (vol 16, pg 575, 2015).
In: Trials
17
[PDF, 357kB]
Yardley, Denise A.; Brufsky, Adam; Coleman, Robert E.; Conte, Pierfranco F.; Cortes, Javier; Glueck, Stefan; Nabholtz, Jean-Mark A.; O'Shaughnessy, Joyce; Beck, Robert M.; Ko, Amy; Renschler, Markus F.; Barton, Debora und Harbeck, Nadia
(2015):
Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.
In: Trials
16:575
[PDF, 1MB]